21047 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof Isomerases (5)
COMPOSITIONS COMPRISING PROTEIN DISULFIDE ISOMERASE AND METHODS OF PRODUCTION AND USE THEREOF
#2METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING FOOD ALLERGIES
#3DESIGN AND CONSTRUCTION OF EVOLUTIONARY-GUIDED "SELECTION GENE DRIVE" THERAPY
#4SUCROSE ISOMERASES AS FOOD AND NUTRITIONAL SUPPLEMENTS
#5ASPARAGINE RACEMASE AND USES THEREOF
#6THIOESTER CATIONIC LIPIDS
#7MODIFIED CASPASE-9 POLYPEPTIDES AND METHODS OF USE THEREOF
#8USE OF LOW pH ACTIVE ALPHA-1,4;/1,6-GLYCOSIDE HYDROLASES (GLCH) AS A FEED ADDITIVE FOR RUMINANTS TO ENHANCE STARCH DIGESTION
#9AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#10POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA
#11COMPOSITIONS, SYSTEMS AND METHODS OF RNA EDITING USING DKC1
#12COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS
#13POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA
#14COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ACTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN
#15COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS
#16COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION
#17HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH
#18COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS
#19COMPOSITION DERIVED FROM MAMMALIAN UMBILICAL CORD AND WHARTONS JELLY FOR USE IN THERAPEUTIC AND REGENERATIVE APPLICATIONS
#20COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
#21METHODS FOR INDUCING SELECTIVE APOPTOSIS
#22POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
#23Tricine and Citric Acid Lipids
#24METABOLIC THERAPY FOR OXIDATIVE STRESS IN THE BRAIN THROUGH TARGETED NEURONAL CATABOLISM OF N-ACETYL-ASPARTIC ACID
#25Modified caspase-9 polypeptides and methods of use thereof
#26DYNAMIC COVALENTLY LINKED HYDROGELS AS STABILIZATION NETWORK PLATFORMS
#27METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS
#28FUSOGENIC LIPID NANOPARTICLES FOR THE TARGET CELL-SPECIFIC PRODUCTION OF RAPAMYCIN INDUCIBLE THERAPEUTIC PROTEINS
#29METHODS AND COMPOSITIONS FOR INCREASING SIALIC ACID PRODUCTION AND TREATING SIALIC RELATED DISEASE CONDITIONS
#30Agent for use in the case of fructose intolerance
#31Thioester cationic lipids
#32CYCLOPHILIN 40 FOR REDUCTION OF NEUROTOXIC FIBRILS AND TREATMENT OF NEURODEGENERATIVE DISEASES
#33USE OF LOW pH ACTIVE ALPHA-1,4;/1,6-GLYCOSIDE HYDROLASES (GLCH) AS A FEED ADDITIVE FOR RUMINANTS TO ENHANCE STARCH DIGESTION
#34Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#35Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#36Cationic lipids comprising a steroidal moiety
#37SUCROSE ISOMERASES AS FOOD AND NUTRITIONAL SUPPLEMENTS
#38ENGINEERED BACTERIA EXPRESSING RACEMASE FOR TREATING DISEASES ASSOCIATED WITH HYPERAMMONEMIA
#39Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
#40Method of making PDIA2 and compositions containing PDIA2
#41CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALLING SYSTEM
#42Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid
#43Method for inducing production of vascular endothelial growth factor
#44POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE
#45Compositions and methods for selective elimination and replacement of hematopoietic stem cells
#46Polynucleotides encoding methylmalonyl-CoA mutase
#47METHODS FOR INDUCING SELECTIVE APOPTOSIS
#48REDUCTION OF LIPASE ACTIVITY IN PRODUCT FORMULATIONS
#49Method of treating type I diabetes using an AAV vector encoding uracortin 2
#50Regulating chimeric antigen receptors
#51THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
#52Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
#53COMPOSITIONS AND USES THEREOF
#54Agent for use in the case of fructose intolerance
#55Drug composition for angiogenesis therapy
#56CYCLOPHILIN 40 FOR REDUCTION OF NEUROTOXIC FIBRILS AND TREATMENT OF NEURODEGENERATIVE DISEASES
#57Modified caspase-9 polypeptides and methods of use thereof
#58METHODS OF TREATING CANCER OF THE CENTRAL NERVOUS SYSTEM
#59Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
#60Agent for use in the case of fructose intolerance
#61Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#62Polynucleotides encoding methylmalonyl-CoA mutase
#63METHODS FOR INDUCING SELECTIVE APOPTOSIS
#64Polynucleotides encoding methylmalonyl-CoA mutase
#65MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF
#66Methods for inducing selective apoptosis
#67Reduction of lipase activity in product formulations
#68Agent for use in the case of fructose intolerance
#69Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid
#70TAGGED FORM OF MUT ENZYME, GENETIC CONSTRUCTS INCORPORATING IT, AND ITS USE IN GENE THEREAPY
#71Method of treating type I diabetes using an AAV vector encoding uracortin 2
#72Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
#73AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#74Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders
#75Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#76Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#77Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#78Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#79METHOD FOR INDUCING PRODUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
#80CRYSTALLIZED XYLOSE ISOMERASE IN PREVENTION OF THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
#81METHODS OF USING CYCLOOXYGENASE-PROSTACYCLIN SYNTHASE FUSION GENE
#82Modified Caspase polypeptides and uses thereof
#83Chimeric antigen receptor (CAR) signalling system
#84Reduction of lipase activity in product formulations
#85Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#86HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS
#87Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT
#88AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#89Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
#90METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS
#91HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN
#92ISOMERASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM
#93Methods for inducing selective apoptosis
#94CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF
#95Methods of treating cancer of the central nervous system
#96Composition for preventing hair loss or enhancing hair growth comprising cyclophilin A
#97Methods for the treatment and diagnosis of bone mineral density related diseases
#98Method of treating or retarding the development of blindness
#99Agent for use in the case of disorders of blood sugar metabolism, including diabetes
#100Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
#101EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS
#102Methods for regulating protein function in cells in vivo using synthetic small molecules
#103MATERIAL COMBINATION FOR TREATING INFLAMMATORY OR INFECTIOUS DISEASES
#104Eye drop composition for prevention and treatment of ophthalmic diseases containing fusion protein of FK506 binding protein
#105Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid
#106Agent for use in the case of fructose intolerance
#107Agent for use in the case of fructose intolerance
#108METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS
#109Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy
#110Agent for use in the case of fructose intolerance
#111Agent for use in the case of fructose intolerance
#112Agent for use in the case of fructose intolerance
#113Methods for diagnosing and treating alzheimer's disease (AD) using the molecules that stabilize intracellular calcium (Ca) release
#114METHODS AND COMPOSITIONS FOR INCREASING SIALIC ACID PRODUCTION AND TREATING SIALIC RELATED DISEASE CONDITIONS
#115Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
#116METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS
#117Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders
#118DRUG COMPOSITION FOR ANGIOGENESIS THERAPY
#119LIPOCALIN-TYPE PROSTAGLANDIN D2 SYNTHASE AS A BIOMARKER FOR LUNG CANCER PROGRESSION AND PROGNOSIS
#120Methods for inducing selective apoptosis
#121Treatment of fructose malabsorption
#122STIMULI-RESPONSIVE HYDROGEL
#123Methods of treating cancer of the central nervous system
#124Isomerases, nucleic acids encoding them and methods for making and using them
#125Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases
#126Method of treating or retarding the development of blindness
#127Compositions and methods for angiogenic therapy utilizing genes encoding ets-1
#128Apoptosis inducer for cancer cell
#129Method for regulating protein function in cells in vivo using synthetic small molecules
#130COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#131HYBRID PROTEIN THAT CONVERTS ARACHIDONIC ACID INTO PROSTACYCLIN
#132Agent for use in the case of fructose intolerance
#133USE OF SECRETED PROTEIN PRODUCTS FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME
#134APOPTOSIS METHODS, GENES AND PROTEINS
#135AGENT FOR USE IN THE CASE OF DISORDERS OF BLOOD SUGAR METABOLISM, INCLUDING DIABETES
#136AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#137Method of Treating or Retarding the Development of Blindness
#138AGENT FOR REDUCING THE USEABLE CALORIE CONTENT OF FOOD AND FOR THERAPEUTIC REDUCTION OF WEIGHT, IN PARTICULAR FOR USE IN THE CASE OF ADIPOSITY (OBESITY)
#139Blockade of Pin1 Prevents Cytokine Production by Activated Immune Cells
#140METHODS AND COMPOSITIONS FOR AFFECTING CYCLOPHILIN A REGULATION OF KINASES IN MODULATING CELLULAR ACTIVITIES
#141SERVICE FOR EFFECTING LOCALIZED, NON-SYSTEMIC AND SYSTEMIC, IMMUNOGENIC TREATMENT OF CANCER USING ERP57 TRANSLOCATION
#142ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
#143Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
#144Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
#145Regulation of cell migration and adhesion
#146USE OF CYCLOPHILIN AS ANTIOXIDANT AND PREVENTION OF CYCLOSPORIN A-INDUCED TOXICITY IN CELL TRANSPLANTATION BY OVEREXPRESSION OF CYCLOPHILIN
#147Neuroactive agents and methods of their use
#148Protein Disulfide Isomerase and ABC Transporter Homologous Proteins Involved in the Regulation of Energy Homeostasis
#149Macrocylic oximyl hepatitis C protease inhibitors
#150NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY NKG2D-POSITIVE CD4+ CELLS
#151Use of Secreted Protein Products for Preventing and Treating Pancreatic Diseases and/or Obesity and/or Metabolic Syndrome
#152Apoptosis Inducer for Cancer Cell
#153Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
#154Method of treating or retarding the development of blindness
#155Methods and compositions for modulating somatolactogenic functions
#156Blockade of Pin1 prevents cytokine production by activated immune cells
#157Werner's syndrome helicase as a target for anti -HIV/AIDS therapy
#158Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
#159Protein markers for pharmaceuticals and related toxicity
#160Methods and compositions for regulating protein-protein interactions
#161Regulation of cell migration and adhesion
#162Regulation of matrix metalloproteinases by PSP94 family members
#163Use of cyclophilin as antioxidant and prevention of cyclosporin a-induced toxicity in cell transplantation by overexpression of cyclophilin